Because of its morbidity and lethality, bacterial meningitis remains a major medical concern throughout the world. The emergence of bacteria not susceptible to standard antibacterial agents in meningitis of children and immunocompromised adults has stimulated the search for alternative drugs. Broad-spectrum cephalosporins have a broad range of in vitro antibacterial activities, including that against most organisms responsible for purulent meningitis (6, 7, 19) , and have been successfully applied as single agents for this indication in children and adults (3, 9, 29, 34, 37) . Cefotaxime and ceftriaxone have been recommended by several authors for initial therapy of unidentified purulent meningitis in children and adults (for examples, see references 15 and 41) .
In the presence of inflamed meninges, therapeutic concentrations of both cefotaxime and ceftriaxone in cerebrospinal fluid (CSF) have been reported previously (3, 9, 22, 34) . However, in encephalitis, in Lyme borreliosis, in some cases of brain abscess and early meningitis, or in the course of meningitis, when the blood-CSF barrier begins to recover, only minor impairment of the blood-CSF barrier may be present (2, 31) . Similarly, dexamethasone, recommended recently for adjunctive therapy of bacterial meningitis, rapidly reduced meningeal inflammation (21) and thereby decreased drug penetration into CSF. To ensure successful therapy and to prevent a relapse in these conditions, any antibiotic suggested for the treatment of central nervous system infections should also attain therapeutic concentrations in CSF with uninflamed meninges. The present study MATERIALS AND METHODS Thirteen patients who had undergone external ventriculostomies for occlusive hydrocephalus received either cefotaxime (n = 6) Concentrations in serum and CSF were measured by high-performance liquid chromatography using isocratic systems: separation of deproteinized cefotaxime and ceftriaxone samples (injection volume, 30 ,ul) was performed at 35°C on C18 reverse-phase columns (Spherisorb ODS II, 250 by 4.6 mm) with mobile phases containing phosphate buffer, acetonitrile, and ion-pairing reagents. Cefotaxime was eluted at 10.8 min, and desacetylcefotaxime was eluted at 5.5 min; they were detected by UV absorption at 254 nm. Ceftriaxone was eluted at 4.9 min and was detected with 274-nm UV light. Peak areas of the samples quantitated by using personal computer integrator software (Nelson Analytical, Cupertino, Calif.) were compared with the areas of serum and CSF samples spiked with standard solutions of cefotaxime, desacetylcefotaxime, and ceftriaxone processed identically. For noncompartmental and compartmental pharmacokinetic analyses, the programs Excel 2.2 (Microsoft Co., Redmond, Wash.) and Topfit 1.0 (Godecke-ScheringThomae, Freiburg-Berlin-Biberach, Germany) were used.
Peak concentrations in serum and CSF (Cm.s and Cm.CSF, respectively) and time from the end of the infusion to the peak concentrations (Tm,s and TmnCSF) were taken directly from the concentration-time curves. Elimination rate constants (kei) were determined by log-linear regression analysis, and half-lives at the rapid elimination phase (t1/2.) were determined as ln2/ke,. patients were analyzed by two-and three-compartment models. The Akaike Information Criterion was used for model discrimination.
RESULTS
Maximum concentrations of cefotaxime and ceftriaxone in serum were attained at the end of the drug infusions; levels of desacetylcefotaxime in serum were maximal 0 to 1 h after the end of the infusions (median = 0.08 h).
The distribution and elimination of cefotaxime in serum were adequately described by a three-compartment model: after a short distribution phase, the elimination half-life of the early phase (t41213) was 0.45 to 0.95 h (median = 0.50 h; n = 6), and that of the late phase (t1/2rS) was Tables 2 through 6 .
Antibiotic concentrations in CSF were maximal after the end of the infusions and indicated slow drug passage into CSF: the respective Tm.CSF of cefotaxime, desacetylcefotaxime, and ceftriaxone were 0.5 to 8 h (median = 3 h; n = 6), 0.25 to 16 h (median = 8 h; n = 5), and 1 to 16 h (median = 12 h; n = 5). Elimination rates of cefotaxime, desacetylcefotaxime, and ceftriaxone from CSF were compatible with a first-order elimination ( Fig. 1 and 2 ). The elimination half-life of cefotaxime in CSF (tl/23CsF) was estimated as 5.0 to 26.9 h (median = 9.3 h; n = 5), and that of ceftriaxone was estimated as 15.7 to 18.4 h (median = 16.8 h; n = 3). With cefotaxime, tl/23CSF exceeded the corresponding serum parameter by a factor of 10 to 41, and with ceftriaxone tl/213CSF was 1.5 to 2.5 times greater than tj/213s (Tables 2 through 6 ).
Because of the different shapes of the concentration-time curves, the ratio between corresponding antibiotic concentrations in CSF and serum (CCSF/Cs) was not constant but increased with time. The hysteresis loops of patient 1 (cefotaxime) and patient 7 (ceftriaxone) illustrate this fact (Fig. 3) . When the AUCCSF was related to the AUCS, the AUCCsF/AUCs ratio ranged from 0.02 to 0.19 (median = 0.08; n = 5) with cefotaxime and from 0.002 to 0.008 (median = 0.003; n = 5) with ceftriaxone. When AUC,O,CSF was related to AUCOs, the AUC ,OcsF/AUC-o_Os ratio of cefotaxime was 0.03 to 0.21 (median = 0.12; n = 5) compared with 0.006 to 0.018 (median = 0.007; n = 5) for ceftriaxone. antibiotics achieved concentrations in CSF several times higher than those in the present study (1, 3, 4, 6, 9, 10, 16, 20, 22, 30) . Elimination of both antibiotics in CSF was considerably slower than that in serum. On average, the t1/23CSF of ceftriaxone was slower (median = 16.8 h) than the tl/213CSF of cefotaxime (median = 9.3 h). In one neonate receiving ceftriaxone, the decay in CSF paralleled the plasma concentration-time curve (22) . In contrast, previous work (7, (24) (25) (26) (27) and the present results indicate that the rate of decline of drug concentrations is slower in CSF than in blood. This is consistent with physiological evidence. A lag of elimination 
DISCUSSION
The t112 of ceftriaxone in serum (median = 10.2 h) was slightly higher than that reported before (7, 19, 28) . This may be due to the fact that we studied only critically ill patients. In contrast to results of several previous investigations (7, 19) , cefotaxime elimination in serum did not approximate a single-exponential decay: tl,2s3S was shorter and tl12rs was longer than the tj,2 found by others (7, 19) . They were close to the early and terminal t1j2 estimated by Ings et al. (17) after measuring cefotaxime concentrations in serum by a microbiologic assay. Since the rate of decline slowed at concentrations in serum below 1 mg/liter, ti/2rs is not noticed with less sensitive assays and may be of clinical relevance only with very sensitive pathogens. Similarly, a slow elimination phase has recently been described for penicillin G (11) . Desacetylcefotaxime in serum followed a first-order elimination.
Maximum levels in CSF achieved after a single dose (2 g/30 min) of cefotaxime or ceftriaxone did not differ substantially in the present study. In contrast, the AUCo,0csF/ AUC,Os ratio was 1 order of magnitude lower with ceftriaxone than with cefotaxime. The main reasons for this behavior probably were the high serum protein binding of ceftriaxone (90 to 95% compared with 40% for cefotaxime) (7, 19) and the higher molecular weight of ceftriaxone (598.5 versus 425.5) (40) .
The CmaxCSF levels measured by us were considerably smaller than concentrations reported for ceftriaxone in lumbar CSF with uninflamed meninges (5) but were comparable to concentrations reported for cefotaxime in CSF with intact meninges (6, 18) and in Lyme disease (31, 32) . Cm. was attained later with ceftriaxone than with cefotaxime. In fully developed bacterial meningitis in children and adults, both from CSF compared with that from blood originates from the slow CSF turnover and from the even slower drainage of interstitial brain fluid into CSF (8, 35) . Similarly, in human brain abscesses the ratio of concentrations of cefotaxime and desacetylcefotaxime in abscesses to those in plasma increased with the time interval between cefotaxime dosing and abscess fluid sampling (39) .
Ceftriaxone and cefotaxime have identical antimicrobial spectra. The maximum concentrations of both drugs in CSF achieved in the present study exceeded the MICs for highly susceptible bacteria (Neisseria meningitidis, Haemophilus influenzae, penicillin G-sensitive Streptococcus pneumoniae, Borrelia burgdorferi, and some members of the family Enterobacteniaceae) approximately 10-fold (7, 13, 14, 19, 32) and therefore should be bactericidal in vivo. However, these levels should not be relied on to inhibit the growth of moderately susceptible bacteria, including relatively or fully penicillin adults (38, 42) , are resistant to newer cephalosporins (6, 7, 19) .
Desacetylcefotaxime, the main metabolite of cefotaxime, possesses independent antibacterial activity. It is less active than the parent compound (19) . Desacetylcefotaxime and cefotaxime act synergistically in a 1:1 ratio but not in a 0.2:1 ratio (14) . In the present study, the desacetylcefotaxime/ cefotaxime ratios varied, usually increasing with time after the end of the infusion. Ratios of the AUCCSF of desacetylcefotaxime and cefotaxime in the individual patients ranged from 0.18 to 0.41. Because of the variability of the ratios, the synergy between cefotaxime and desacetylcefotaxime cannot be counted upon in the clinical routine.
In conclusion, with highly susceptible organisms, both cefotaxime and ceftriaxone achieve therapeutic levels in CSF with inflamed and uninflamed meninges. With moderately susceptible bacteria, the levels in CSF observed in this study after infusion of 2 g of cefotaxime or ceftriaxone were probably subtherapeutic. This may compromise therapy when meningeal inflammation is less pronounced or resolves in the course of the illness. With cefotaxime, maximum concentrations in CSF were attained earlier than with ceftriaxone. Although the long persistence of both ceftriaxone and cefotaxime in CSF would permit long dosage intervals, the rapid elimination of cefotaxime in blood suggests distances between the single infusions of not more than 8 h with meningitis. The lack of a decisive advantage of one drug when they were compared with each other under the conditions studied by us is paralleled by clinical studies of bacterial meningitis and Lyme disease in which they were equally effective (12, 29, 32) .
